Complete Patent Ductus Arteriosus Occlusion Research Articles

Transcatheter closure of persistent ductus arteriosus in 2 to 6 kg infants: Preliminary results from an international, retrospective study

Transcatheter patent ductus arteriosus (PDA) closure has proved to be safe in < 2 kg preterm infants, but major safety concerns remain when applied to the 2 to 6 kg body weight range. The aim of the present work is to assess efficacy and safety of transcatheter PDA occlusion in low-body-weight infants. Patients weighing 2 to 6 kg who underwent attempted transcatheter closure of an isolated PDA in 10 tertiary pediatric cardiology units (5 countries, 2000 to 2022) were retrospectively analyzed to review the outcome. A total of 339 infants (m/f sex ratio: 0.53; 56% ex-preterm, median age: 5.3 months [9 days–41 months], median weight: 4.7 kg [2 kg–6 kg]) were analyzed. Patients were all symptomatic (respiratory support: 33.2%, hospitalization for heart failure: 49.6%, nutrition care: 45.7%) with a hemodynamically significant PDA. Ductus was large (minimal ductal diameter: 4.2 ± 1.6 mm) and mainly conical (Krichenko type A: 57%) or tubular (Krichenko type C: 23%). Procedure was performed under both fluoroscopy (fluoro time: 10.7 ± 7.3 min) and transthoracic echocardiography guidance in all patients, with both arterial and venous femoral access (90%). Successful device implantation and complete PDA occlusion was achieved in 320 (94.4%) patients using devices in 91% (mainly ADO-I: 43.1%, ADO-IIAS: 20.0%, AVP-II: 8.0%, ODO: 5.3%, ADO-II: 3.5%, MFO: 2.1%, AVP-IV: 0.9%) vs. coils in 9%. Moderate to major complications occurred in 27 (8.0%) patients, including one death (0.3%) after delayed device embolization to descending aorta, device embolization (5.3%) and device-related obstruction of the left pulmonary artery (1.5%) or of the aorta (0.3%). These are preliminary data from a wider international study. We plan to collect both surgical and transcatheter cases in a wider series (40 tertiary centers, 20 countries), i.e. the largest cohort to date. This will allow better delineation of risk stratification, to keep refining indications for device closure in low-body-weight infants and achieve ever-safer results.

Early experience with the Micro Plug Set for preterm patent ductus arteriosus closure.

We intend to describe early experience using a new, commercially available Micro Plug Set for preterm neonate and infant transcatheter patent ductus arteriosus (PDA) occlusion. Transcatheter PDA occlusion in premature neonates and small infants is safe and effective. The procedure is early in its evolution. Procedural and short-term outcomes of preterm neonates and infants undergoing transcatheter PDA occlusion with a new, commercially available device were reviewed. Eight preterm neonates and infants born at median 27 weeks gestation (23-36 weeks) underwent transcatheter PDA device closure with the Micro Plug Set. The device is short (2.5 mm) with a range of diameters (3, 4, 5, 6 mm) and delivered through a microcatheter. Procedures were performed at median 41 days of age (12-88 days) and at 1690 g (760-3,310 g). Transvenous PDA device occlusion was performed with fluoroscopic and echocardiography guidance. All procedures were successful with complete PDA occlusion. There were no procedural or short-term adverse events. Preterm neonate and infant transcatheter PDA device closure with a new, commercially available short and microcatheter delivered device (Micro Plug Set) was safe and effective in a small, early series of patients.

Adult patent Ductus Arteriosus complicated by endocarditis and hemolytic anemia

An adult with a large patent ductus arteriosus may present with fatigue, dyspnea or palpitations or in rare presentation with endocarditis. The case illustrated unique role of vegetation of endocarditis in hemolytic anemia in adult with patent ductus arteriosus (PDA). Despite treatment of endocarditis with complete course of appropriate antibiotic therapy and normality of C- reactive protein, erythrocyte sedimentation rate and leukocytosis and wellness of general condition, transthoracic echocardiography revealed large vegetation in PDA lumen, surgical closure of PDA completely relieved hemolysis, and fragmented red cell disappeared from peripheral blood smear. The 3-month follow-up revealed complete occlusion of PDA and abolishment of hemolytic anemia confirmed by clinical and laboratory examination.

Transesophageal Echocardiography Guided Patent Ductus Arteriosus Occlusion with a Duct Occluder

Angiography and fluoroscopy are the standard methods to guide transcatheter occlusion of patent ductus arteriosus (PDA). The use of iodinated contrast agents and radiation exposure pose risks of animals and staff. To assess feasibility of transesophageal echocardiography (TEE) for device size selection and procedure monitoring for PDA occlusion with a duct occluder (DO) without the use of angiography. Eighty client-owned dogs with left-to-right PDA. Prospective study. Dogs with left-to-right PDA undergoing transcatheter occlusion were included. Procedures were performed without angiography and device size selection was based on TEE measurements. Procedures were monitored with simultaneous TEE and fluoroscopy and both methods were compared. Visualization of the ductus and dimensions obtained by TEE and transthoracic echocardiography (TTE) were compared. Complete PDA occlusion was achieved in 79/80 cases. TEE was consistently superior to TTE for PDA visualization and the latter showed higher values for ductal dimensions when compared to the former. TEE provided adequate procedure monitoring in 73 cases (91%). Fluoroscopy exposure time (2.77 ± 1.2 minutes (mean, SD)) was lower than previously reported for the same procedure. TEE is a useful and efficient tool for device size selection and can be used for procedure monitoring in most cases. Fluoroscopy exposure time can be reduced and the use of contrast agents can be avoided. However, fluoroscopy is required in a minority of cases when TEE monitoring is not feasible or incomplete and should be available for this procedure.

A New Double-Cone Nitinol Device for PDA Occlusion: Design, Manufacturing and Initial In Vivo Results

Use of occluder devices for a patent ductus arteriosus (PDA) closure is restricted to small diameter PDAs and involves high device costs. The objective of this study was to develop a new nitinol implant for the closure of a PDA and to evaluate its safety and efficacy in an animal model. The design consists of a device that promotes thrombus formation in the PDA. The device has a double-cone shape with their vertices joined. The cones are made of a nitinol wire helix with dacron fibers attached. The proximal end of the helix can be screwed to a conventional catheter release wire. In vitro testing was performed to verify the effectiveness of the implantation of the device and its releasing system; all trials (n = 30) were successful, showing accurate placement and release of the device. Complete and successful implantation of the device was achieved in all in vivo experiments (n = 5). There was one case of embolization due to premature detachment; a second device was successfully implanted. Histological evaluation after 42.3 +/- 3.1 days demonstrated complete PDA occlusion. The retrieved PDA showed total closure of the defect, endothelization of the PDA outlets and proper lodging of the device.

Outcome of Percutaneous Transarterial Coil Occlusion in Patients with Isolated Patent Ductus Arteriosus Using an Upstream-and-Push Maneuver

There are limited data on the outcome of percutaneous transarterial coil occlusion for isolated patent ductus arteriosus (PDA) in Taiwan. This study evaluated the 2-year outcome of 52 patients with isolated PDA who received percutaneous transarterial coil occlusion by an upstream-and-push maneuver. From July 1997 to June 2002, a total of 52 patients (25 infants, 27 children) underwent occlusion of PDA with standard Gianturco coils. There were 39 females and 13 males. Patient age ranged between 7 days and 14 years, and weight was between 3 and 45 kg. Percutaneous transarterial coil occlusion was performed by an upstream-and-push maneuver. Chest auscultations, chest radiographs, and Doppler echocardiography were performed in all patients within 24 hours, and 1, 3, 6, 12 and 24 months after coil occlusion. Mean PDA diameter at the pulmonary end was 2.34 +/- 1.00 mm (range, 1.00-4.80 mm). Angiographic classification was megaphone type in 32 patients, window type in seven, tubular type in six, aneurysmal type in three, and elongated conical type in four. Complete PDA occlusion was performed with a single coil in 41 (79%) patients and with multiple coils in 11 (21%). The mean ratio of pulmonary to systemic blood flow was 1.95 +/- 0.95 (range, 1.10-5.80) before the procedure, and 1.02 +/- 0.04 (range, 1.00-1.20) after the procedure (p < 0.001). Immediate occlusion of the ductus was achieved 15 minutes after the procedure in 44 (85%) patients. Occlusion was achieved in 92% of patients within 24 hours and in 100% of patients by the 1-month follow-up. Follow-up at 24 months after the procedure revealed no complications. Percutaneous transarterial coil occlusion with 5-loop Gianturco coils can be effectively and safely achieved in patients with a PDA minimum diameter < 5 mm.

Early reopening and recanalization after successful coil occlusion of the patent ductus arteriosus

Background Controversy exists regarding early reopening and recanalization after successful (complete) coil occlusion of the patent ductus arteriosus (PDA). Methods Patients with successful PDA coil occlusion were reviewed with regard to PDA size and type, coil size, number of coils, and delivery technique. Follow-up echocardiograms at <24 hours, 6 months, and >12 months were reviewed for residual PDA shunt, left pulmonary artery (LPA) stenosis, and aortic obstruction. Results Successful coil occlusion was achieved in 94 patients. On the initial (<24 hours) echocardiogram, 76 of 92 (83%) had complete PDA occlusion, 5 of 92 (5%) had mild LPA stenosis, and no patient had aortic obstruction. Follow-up at 6 months was available in 70 patients, 57 with complete occlusion on the initial echocardiogram. PDA reopening was found in 3 of 57 patients (5%). Larger PDA diameter was associated with residual shunt (2.40 ± 0.40 mm versus 1.87 ± 0.53 mm; P <.01). Disagreement between the initial and 6-month echocardiogram was found in 11 of 70 patients (16%). Intermediate follow-up (median, 30 months; range, 12 months to 5.3 years) was available in 46 patients, 38 with complete occlusion on the 6-month echocardiogram. No patient (0 of 38) with a normal echocardiogram at 6 months developed recanalization, LPA stenosis, or aortic obstruction. Conclusion These data suggest that: (1) routine echocardiography immediately after PDA coil occlusion is unnecessary; (2) early PDA reopening is uncommon; and (3) PDA recanalization does not occur if complete echocardiographic closure is documented 6 months after coil occlusion. Additional follow-up examination in these patients may not be necessary. (Am Heart J 2002;143:889-93.)

Follow-up results of transvenous occlusion of patent ductus arteriosus with the buttoned device

OBJECTIVESThe purpose of this presentation is to document results of buttoned device (BD) occlusion of patent ductus arteriosus (PDA) in a large number of patients with particular emphasis on long-term follow-up in an attempt to provide evidence for feasibility, safety and effectiveness of this method of PDA closure.BACKGROUNDImmediate and short-term results of BD occlusion of PDA have been documented in a limited number of children.METHODSDuring a six-year period ending August 1996, transcatheter BD closure of PDA was attempted in 284 patients, ages 0.3 to 92 years (median 7) under a protocol approved by the local institutional review boards and FDA with an investigational device exemption in U.S. cases.RESULTSThe PDAs measured 1 to 15 mm (median 4) at the narrowest diameter; 20 were larger than 8 mm and 10 larger than 10 mm. They were occluded with devices measuring from 15 to 35 mm delivered via 7F (N = 140) or 8F (N = 144) sheaths. Successful implantation of the device was accomplished in 278 (98%) of 284 patients. The Qp:Qs decreased from 1.8 ± 0.6 (mean ± SD) to 1.09 ± 0.19 (p < 0.001). Effective occlusion defined as no (N = 167 [60%]) or trivial (N = 79 [28%]) residual shunt was achieved in 246 (88%) patients. All types of PDAs, irrespective of the shape (conical, tubular or short), size (small or large) or length (short or long) of the PDA and previously implanted Rashkind devices, could be occluded. Follow-up data, 1 to 60 months (median 24) after device implantation, were available in 234 (84%) patients. Seven (3%) patients required reintervention to treat residual shunt with (N = 2) or without (N = 5) hemolysis. Actuarial reintervention-free rates were 95% at 1 and 5 years. There was gradual reduction of actuarial residual shunts and were 40%, 28%, 21%, 14%, 11%, 10%, 6% and 0% respectively at 1 day, 1, 6, 12, 24, 36, 48 and 60 months after device implantation. Incorporation of folding plug over the button loop in 10 additional patients produced immediate and complete occlusion of PDA.CONCLUSIONSThis large multiinstitutional experience confirms the feasibility, safety and effectiveness of buttoned device closure of PDAs. All types of PDAs irrespective of the shape, length and diameter can be effectively occluded. Incorporation of folding plug over the button loop produces complete PDA occlusion at the time of device implantation.

783-2 Follow-up After Coil Occlusion of Patent Ductus Arteriosus

To define the prevalence and fate of residual shunts after Gianturco coil occlusion of patent ductus arteriosus (PDA), 50 pts were followed prospectively after PDA coil occlusion at CS Mott Children's Hospital between 10/92 and 8/94. Evidence of residual shunt was sought on immediate post-coil aortic angiograms and on color-flow Doppler echocardiograms performed in follow-up. Survival analysis of residual PDA shunting was analyzed by the Kaplan-Meier method, and the effect of minimum PDA angiographic size on residual shunting was determined by ANOVA. The 50 pts, median age 4.4 years (range 0.4-62), have been followed for ≤ 20 months (mean ± SD: 8 ± 6). PDA minimum diameter was 1.6 ± 0.8 mm (range 0.5–3.3). Complete PDA occlusion was noted immediately in 29 pts (58%); tiny residual shunts closed spontaneously 1–20 months after coil occlusion in 12 pts (24%). Tiny residual shunts persisted have undergone a second coil occlusion with immediate complete closure. Survival analysis (graph) estimates 20 month prevalence of residual shunts at 7 ± 6% after 1 coil procedure and 4 ± 4% after all coil procedures. PDA diameter significantly influenced residual shunting, being 1.3 ± 0.7 mm in pts with immediate closure, 1.9 ± 0.8 mm with spontaneous shunt closure in follow-up, and 2.0 ± 0.9 mm with persistent residual shunt or second coil placement (p = 0.02). 1) Survival analysis estimates 93% complete PDA closure after a single coil occlusion procedure; 2) Residual shunts are associated with larger PDA diameter, and most close spontaneously; and 3) When necessary, a second coil occlusion has been uniformly successful.